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The limited supply and expansion capacity of primary human hepatocytes presents major challenges for
pharmaceutical applications and development of cell-based therapies for liver diseases. Now in Cell Stem
Cell, two papers demonstrate efficient direct reprogramming of human fibroblasts into induced hepatocytes,
which exhibit metabolic properties similar to primary hepatocytes.The liver is a unique organ that performs
a broad spectrum of functions. It stores
reserves of iron, vitamins, and minerals
and detoxifies alcohol, drugs, and other
chemicals that accumulate in the blood-
stream. The liver also produces bile, albu-
min, and blood-clotting factors. Finally,
the liver performs an essential metabolic
activity by storing glycogen. These tasks
aremanaged by one cell type, the hepato-
cyte, which constitutes the main cellular
unit of the liver. Genetic disorders or in-
juries that prevent the liver from carrying
out these essential activities result in life-
threatening diagnosis and end-stage liver
diseases that require organ transplanta-
tion. Thus, generating large quantities of
hepatocytes asanalternative to liver trans-
plants is a major objective for drug devel-
opment and regenerative medicine. How-
ever, freshly isolated hepatocytes come
in limited supply, often from donated or-
gans that are of poor quality, and are
impossible to expand in large quantities
in vitro. Therefore, deriving hepatocytes
from stem cell populations such as human
pluripotent stem cells (hPSCs) presents anattractive alternative to primary cells. Now
in Cell Stem Cell, two studies, from the
groups of Lijian Hui and Hongkui Deng,
demonstrate an additional approach by
directly reprogrammingfibroblasts intohu-
man induced hepatocytes (hiHeps) (Du
et al., 2014; Huang et al., 2014).
hPSCs have been used advantageously
to produce hepatocytes for disease
modeling (Rashid et al., 2010) and for
developmental studies. However, genera-
tion of cells displaying all the functional
characteristics of mature hepatocytes
has been proven difficult. Indeed, hPSC-
derived hepatocytes uniformly express
fetal markers such as AFP and lack key
metabolic activity associated with adult
cells such as cytochromep450, especially
CyP3A4. Importantly, recent improve-
ments involving 3D cultures (Ogawa
et al., 2013), small molecule screens
(Shanet al., 2013), andalso in vivomatura-
tion with coculture of endothelial cells
(Takebe et al., 2013) have resulted
in important functional improvements,
including the expression of inducible
CyP3A4 and diminished AFP expression.The development of robust pluripotent
stem cell differentiation protocols has
been impaired by the lack of knowledge
concerning the mechanisms that regulate
the functional maturation of the human
liver after birth. Direct reprogramming ap-
proaches could bypass this last limitation
by avoiding the need to mimic a complex
path of development in vitro. Accordingly,
previous reports have shown that over-
expression of Gata4/HNF1alpha/Foxa3
or HNF4a/FoxA1/FoxA2/FoxA3 in mouse
embryonic fibroblasts, following genetic
ablation of p19, enables the production
of induced hepatocyte-like cells (iHep)
(Huang et al., 2011; Sekiya and Suzuki,
2011). These cells can be expanded
in vitro while displaying a limited meta-
bolic activity, and they retain the capacity
to colonize the failing liver of mice lacking
fumarylacetoacetate hydrolase (Fah/),
a common animal model of liver failure
(Azuma et al., 2007).
The two reportspublished in this issueof
Cell StemCell have successfully extended
this approach to human fetal cells. Huang
et al. (2014) report that overexpression of14, March 6, 2014 ª2014 Elsevier Inc. 267
Figure 1. Direct Reprogramming of Human Fetal Fibroblast into Induced Hepatocytes
Human fetal fibroblasts (HFFs) are transduced with two different cocktails of transcription factors. The
transduced cells are then grown in media supporting hepatocytes survival and function. With method 1,
the proliferative capacity of hiHep cells is increased by overexpressing SV40 T antigen 14 days after trans-
duction. In method 2, expression of c-myc and shRNAs targeting p53 allow proliferation of reprogrammed
cells. The expression of shRNA directed against p53 decreases 25 days after transduction, and the cells
are then transferred into a medium allowing functional maturation. The resulting hiHep display functional
characteristics of primary hepatocytes including Albumin and Alpha-Antitrypsin secretion, phase I enzyme
activity including Cyp3A4, phase II metabolic enzyme, and phase III drug transporter expression, choles-
terol uptake, and glycogen storage.
Cell Stem Cell
PreviewsHNF4 (instead of GATA4), HNF1A, and
FOXA3 in fibroblastsallows theproduction
of hiHeps with a conversion rate close to
20%. The second publication relies on
a more complete set of factors (C-MYC,
HNF1A, HNF4A, HNF6, ATF5, PROX1,
CEBPA, and p53 ShRNA) that follow a
developmental rationale, since the cock-
tail includes transcription factors not only
involved in liver bud induction (HNF1A,
HNF4A, HNF6) but also in hepatocyte
specification/maturation (ATF5, PROX1,
and CEBPA). Following this approach,
nearly 80% of the resulting hiHep cells ex-
press Albumin after 30 days ofmaturation.
The efficiency of both methods is remark-
able and suggests that direct reprogram-
ming could be a valuable substitute for
large-scale production of hepatocytes.
Interestingly both groups have developed
novel strategies to bypass the lack of
proliferation associated with direct re-
programming. Huang et al. (2014) used
overexpression of SV40 large T antigen
to establish hiHepLT cells, which can be
grown in vitro. However, the resulting cells
displaydecreasedmetabolic activitywhen
compared to nontransformed hiHep cells.
Du et al. (2014) used simultaneous overex-
pressionofC-MYCandknockdownof p53268 Cell Stem Cell 14, March 6, 2014 ª2014during reprogramming (Figure 1). This pro-
vides the advantage of avoiding forced
proliferation of mature cells, which would
likely be detrimental to their functionality.
In both cases, hiHeps display an
outstanding panel of metabolic activities
including inducible expression and activity
of CyP3A4, at levels comparable to those
of primary hepatocytes. Impressively, Du
et al. (2014) used freshly isolated hepato-
cytes from two donors, which represents
the best possible control. Both publica-
tions also show that hiHeps and primary
hepatocytes share a mutual gene expres-
sion profile and the authors rightly focus
on thegenescommonlyexpressed.Never-
theless, a broad number of genes are also
differentially expressed, demonstrating
differences between hiHep cells and their
natural counterparts. This discrepancy
simplyconfirms thatengineeringcells iden-
tical to primary hepatocytes in vitro is
utopic. Artificially generated cells are likely
to exhibit specific characteristics imposed
by culture systems that only partially repli-
cate the complexity of the natural hepatic
environment.
Finally, both studies validate the
functionality of hiHep cells using three
different mice models for acute liverElsevier Inc.failure. Of particular interest, hiHepLT
can colonize the livers of FRG (Fah//
Rag2//Il2rg/) mice and mice in-
jected with concanavalin A, improving
their survival. These results are impressive
since only adult primary hepatocytes have
been shown to function in the FRG model
(Azuma et al., 2007). Similarly, Du et al.
(2014) show that hiHep can colonize
efficiently the liver of Tet-uPA/Rag2//
gc/ mice and secrete high levels of
human albumin in the plasma of the trans-
planted mice. Both studies also show that
primary hepatocytes have a higher capac-
ity for colonizationwith consistently higher
levels of Albumin secretion. Thus, these
in vivo data certainly confirm the unprece-
dented level of functionality acquired by
hiHep cells but also suggest that they
could be a limited substitute for primary
hepatocytes in the context of cell-based
therapy.
Together these publications establish
that production of highly functional human
hepatocyte-like cells using direct reprog-
ramming approaches is feasible and
thus represent an exciting step toward
the production of an infinite supply of cells
for drug development pipelines and thera-
pies for liver diseases. However, several
challenges remain to be addressed,
including the transfer of this technology
to adult somatic cells especially from pa-
tients with inherited metabolic disorders
for the purpose of disease modeling.
Additionally, the use of direct reprogram-
ming for cell-based therapies also re-
mains uncertain. Indeed, the technologies
currently available to generate hiHeps and
to increase their proliferative capacity are
not compatible with in vivo use. Addition-
ally, hiHeps are a mixed cell population,
since each cell originates from a unique
reprogramming event. This could intro-
duce a large degree of variability and con-
founds quality controls essential for mov-
ing this methodology into the clinic. Thus,
despite the significant progress achieved
by the current publications, further basic
studies are still required to uncover the
mechanisms that orchestrate human liver
development and that ultimately establish
the functional diversity of hepatocytes
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Since the inception of nuclear reprogramming, the parallels between this process and tumorigenesis have
become increasingly apparent. Recent studies by Abad et al. and Ohnishi et al. have now formalized this
connection by demonstrating that the same transcription factors used for reprogramming to pluripotency
drive tumor initiation in vivo.Although experimental conditions allow-
ing nuclear reprogramming in vitro have
been well established (Stadtfeld and Ho-
chedlinger, 2010), whether an in vivo envi-
ronment would also support induced
pluripotent stem cell (iPSC) formation
from adult somatic cells has remained
essentially unexplored. This open ques-
tion within the field is now addressed in
two new studies using doxycycline-
inducible reprogramming factors (Oct3/4,
Klf4, Sox2, and c-Myc; OKSM) in trans-
genic mice (Abad et al., 2013; Ohnishi
et al., 2014). They demonstrate that doxy-
cycline-inducible expression of OKSM in
adults can ultimately lead to formation of
teratomas in multiple organs. Because
the cell-of-origin of this tumor type is typi-
cally a pluripotent cell, these studies indi-
cate that the in vivo milieu is perfectly
amenable to nuclear reprogramming.
Indeed, ex vivo culture of cells derived
from these teratomas or circulating cells
of induced mice yields iPSCs in the
absence of further OKSM induction.
Abad and colleagues additionally demon-
strate that cells reprogrammed in thissetting acquired a more primitive, totipo-
tent state than in-vitro-derived iPSCs.
However, it remains to be determined
how iPSC potency can be so dramatically
affected in these distinct experimental
settings.
While these discoveries are highly sig-
nificant for the iPSC field, of potentially
greater interest are the unexpected in-
sights gained into theassociationbetween
nuclear reprogramming and cellular trans-
formation (Figure 1). A prominent acute ef-
fect of OKSM induction in both studies
was the formation of dysplastic lesions in
multiple tissues, potentially representing
early reprogrammingstepsen route toplu-
ripotency. Asmight be expected given the
initial dependence of in vitro reprogram-
ming on continual expression of exoge-
nous OKSM factors, Ohnishi et al. found
that tissue dysplasia was most often
reversed upon doxycycline withdrawal at
early time points after OKSM induction. A
more prolonged induction period resulted
in formation of tumors in multiple tissues
consisting of undifferentiated dysplastic
cells, which were distinct from teratomas.Strikingly, these tumors were resistant
to doxycycline withdrawal andweremain-
tained independently of transgenic OKSM
expression. The kidney seemed particu-
larly disposed to developing these tumors
and was a focus of study by the authors.
Critically, several lines of evidence indi-
cated that these tumors were derived
from kidney tubule cells that had partially
reprogrammed toward a pluripotent state
(partially reprogrammed transformed
cells; PRTCs). Transcriptional profiling
confirmed that PRTCs had lost tubule-
cell identity and adopted elements of an
embryonic stem cell (ESC) gene-expres-
sion program. Indeed, iPSCs could be
rapidly generated in vitro from tumor
cells upon further OKSM induction.
Further, modification of the reprogram-
ming cassette to omit specific OKSM fac-
tors demonstrated that the presence of
Oct3/4, considered the most critical re-
programming component (Takahashi and
Yamanaka, 2006), was essential for tumor
resistance to doxycycline removal. When
comparing gene expression between
PRTCs and ESCs, key differences were14, March 6, 2014 ª2014 Elsevier Inc. 269
